Brokerages Set Vericel Co. (NASDAQ:VCEL) PT at $63.14

Shares of Vericel Co. (NASDAQ:VCEL) have been given a consensus recommendation of “Buy” by the seven research firms that are presently covering the firm, MarketBeat.com reports. Seven equities research analysts have rated the stock with a buy recommendation. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $62.29.

VCEL has been the topic of a number of recent analyst reports. StockNews.com lowered Vericel from a “hold” rating to a “sell” rating in a report on Friday, February 28th. Stephens reiterated an “overweight” rating and set a $65.00 price target on shares of Vericel in a report on Wednesday, January 15th. HC Wainwright reiterated a “buy” rating and set a $60.00 price target on shares of Vericel in a report on Friday, February 28th. Truist Financial restated a “buy” rating and issued a $61.00 target price (down from $67.00) on shares of Vericel in a research note on Monday. Finally, BTIG Research boosted their target price on Vericel from $56.00 to $66.00 and gave the company a “buy” rating in a research note on Tuesday, November 26th.

Insider Buying and Selling at Vericel

In other news, insider Jonathan Siegal sold 3,908 shares of Vericel stock in a transaction on Tuesday, January 28th. The stock was sold at an average price of $61.99, for a total value of $242,256.92. Following the completion of the transaction, the insider now directly owns 1,206 shares in the company, valued at approximately $74,759.94. The trade was a 76.42 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Robert L. Md Zerbe sold 2,500 shares of Vericel stock in a transaction on Wednesday, February 5th. The shares were sold at an average price of $62.50, for a total value of $156,250.00. Following the completion of the transaction, the director now owns 26,595 shares of the company’s stock, valued at approximately $1,662,187.50. This trade represents a 8.59 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 7,500 shares of company stock worth $466,200 over the last ninety days. 5.20% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Vericel

Hedge funds have recently made changes to their positions in the stock. International Assets Investment Management LLC grew its position in shares of Vericel by 4,126.7% in the third quarter. International Assets Investment Management LLC now owns 634 shares of the biotechnology company’s stock valued at $27,000 after purchasing an additional 619 shares in the last quarter. Arcadia Investment Management Corp MI purchased a new position in Vericel during the fourth quarter worth about $48,000. Farther Finance Advisors LLC grew its position in Vericel by 48.1% during the third quarter. Farther Finance Advisors LLC now owns 1,247 shares of the biotechnology company’s stock worth $53,000 after buying an additional 405 shares in the last quarter. GF Fund Management CO. LTD. purchased a new position in Vericel during the fourth quarter worth about $57,000. Finally, Smartleaf Asset Management LLC grew its position in Vericel by 511.1% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,265 shares of the biotechnology company’s stock worth $70,000 after buying an additional 1,058 shares in the last quarter.

Vericel Trading Up 0.8 %

Shares of Vericel stock opened at $51.53 on Thursday. The business’s fifty day simple moving average is $56.81 and its 200 day simple moving average is $51.93. The firm has a market capitalization of $2.54 billion, a P/E ratio of 858.98 and a beta of 1.72. Vericel has a 12 month low of $39.12 and a 12 month high of $63.00.

Vericel Company Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.